Risk of Secondary Cancers After CAR T Therapy May Be Similar to Risk After Other Cancer Treatments
PHILADELPHIA – The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy...
PHILADELPHIA – The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy...
Patients who would not have otherwise been candidates for surgery achieved successful resection PHILADELPHIA – Patients with liver cancer...
Study highlights potential benefits of broadening eligibility criteria for clinical trials PHILADELPHIA – Patients with treatment-refractory cancers who received...
Transgender or gender non-conforming cancer survivors had higher odds of most conditions compared to cisgender cancer survivors PHILADELPHIA –...
PHILADELPHIA – The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile...
HPV testing eight years after a negative result instead of the recommended five was found comparable to standard cytology...
Among patients over 65 who received an allogeneic hematopoietic stem cell transplant (allo-HCT) for the treatment of acute myeloid...
PHILADELPHIA – The American Association for Cancer Research (AACR) today announced the appointment of Nickolas Papadopoulos, PhD, as editor-in-chief...
Following a single dose of pembrolizumab, FDG PET/CT scans were able to show metabolic changes in tumors that correlated...
PHILADELPHIA – The majority of patients with metastatic colorectal cancer whose cancer did not progress during initial treatment with...